Articles tagged with: Pomalidomide

News»

[ by and | Jun 11, 2013 5:47 pm | 5 Comments ]
ASCO 2013 And Multiple Myeloma: What Were The Highlights?

This year’s meeting of the American Society of Clinical Oncology (ASCO) was held May 31 through June 4 in Chicago.

During the meeting, The Beacon published daily updates that provided over­views of the important multiple myeloma findings presented during the meeting.

Now that the meeting has concluded, the focus shifts to the bigger picture: What were the key findings of the meeting? Were there results with immediate im­pli­ca­­tions for the treatment of multiple myeloma?  Did the research at the meeting represent a major step for­ward for myeloma …

Read the full story »

News»

[ by | Updated: Jun 12, 2013 12:30 pm | 2 Comments ]
ASCO 2013 Multiple Myeloma Update – Day Four: Oral Presentations

This year’s annual meeting of the American Society of Clinical Oncology (ASCO) came to an end yesterday in Chicago.

Monday was the busiest day with regard to myeloma-related research. The day started with an oral presentation session that included eight talks about im­por­tant new myeloma-related research. A poster session in the afternoon included several posters about myeloma-related research.

This article summarizes the most important findings from Monday’s oral pre­sen­ta­tion session. A later article will cover the findings from the after­noon poster session.

The content in our daily updates is based …

Read the full story »

News»

[ by and | Updated: Jun 4, 2013 1:41 pm | One Comment ]
ASCO 2013 Multiple Myeloma Update – Day Three: Poster Presentations

This year’s American Society of Clinical Oncology (ASCO) annual meeting, which is being held in Chicago, began on Friday and goes through Tuesday.

Sunday started with a poster session in which important new research findings were summarized on posters displayed throughout a large conference hall.

The studies presented during the session were on a wide variety of myeloma-related topics, including new treatments being developed for myeloma, currently used regimens, smoldering multiple myeloma, and findings on initial therapy.

Some of the posters included preliminary results from ongoing clinical trials.  Others described …

Read the full story »

News»

[ by | Updated: June 3, 2013 4:45 pm | 5 Comments ]
Pomalidomide Gets Positive Opinion From European Advisory Committee; Approval Expected By End Of Summer

An advisory committee of the European Medicines Agency has issued a positive opinion regarding European approval of pomalidomide for the treatment of cer­tain patients with multiple myeloma.

Specifically, the Committee for Medicinal Products for Human Use (CHMP) rec­om­mended that pomalidomide be approved for use in com­bi­na­tion with dexa­metha­sone (Decadron) for the treatment of re­lapsed and refractory multiple myeloma patients who have received at least two prior therapies, including both Revlimid (lenalidomide) and Velcade (bor­tezo­mib), and have demonstrated disease progression while on their last …

Read the full story »

News»

[ by and | May 24, 2013 4:23 pm | 8 Comments ]
The Future Of Treatment For Multiple Myeloma

In a recent review article published in the journal Clinical Cancer Research, two myeloma experts from the Dana-Farber Cancer Institute, Dr. Nikhil Munshi and Dr. Kenneth Anderson, review the latest strategies in the treatment of multiple myeloma.

In their article, the experts discuss newer therapies that appear to be promising in clinical and preclinical studies.

According to the physicians, combination therapies that specifically target a patient’s genetic form of the disease will be required for long-term disease control and ultimately a cure.

Some Historical Perspective

In their review article, Drs. …

Read the full story »